logo
Plus   Neg
Share
Email

Ipsen's Partner Announces Hold Of Phase III Trials Of IB1001 For Hemophilia B

Ipsen's (IPSEF.PK) partner, Inspiration Biopharmaceuticals Inc., was notified by the Food and Drug Administration or FDA that both studies evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.

The clinical hold impacts 2 ongoing IB1001 clinical trials such as a phase III study evaluating the safety and efficacy of IB1001 to treat and prevent bleeding episodes in adults with hemophilia B, and a phase III study evaluating IB1001 to treat and prevent bleeding episodes in previously treated pediatric subjects with hemophilia B.

The adult study has completed its primary analysis period. Following the FDA's request, Inspiration has notified clinical sites in the U.S. to hold treatment of patients with IB1001. Also, Inspiration Biopharmaceuticals is sharing the FDA directive with regulators in countries outside of the U.S. where the studies are being conducted.

Totally, 86 people with hemophilia B have received IB1001 in trials and, to date, no adverse events related to the development of antibodies to CHO protein have been reported. Moreover, no relationship has been showed between the development of antibodies to CHO protein and the development of any antibodies to factor IX, the company added.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Canadian gold miner IAMGOLD Corp. announced a strategic investment in Tradewind Markets, Inc., a financial technology company that uses blockchain to speed up and streamline digital gold trading. The miner did not elaborate on the investment amount, while Tradewind in its statement said it has closed a $10.6 million strategic placement. Bristol-Myers Squibb Co. (BMY) on Thursday increased adjusted earnings guidance for the full-year 2018 to a range of $3.35 to $3.45 per share from the prior range of $3.15 to $3.30 per share. However, the company lowered reported earnings outlook to a range of $2.70 to $2.80 per share from the previously... Snack and beverage giant PepsiCo Inc. (PEP) on Thursday reported an increase in net income for the first quarter, reflecting higher revenues. Both adjusted earnings per share and net revenues for the quarter beat analysts' estimates. The company also reaffirmed its earnings and revenue outlook for...
Follow RTT